Skip to main content
. Author manuscript; available in PMC: 2024 Sep 1.
Published in final edited form as: Pediatr Blood Cancer. 2023 Jul 21;70(Suppl 6):e30584. doi: 10.1002/pbc.30584

Figure 2. Therapeutic targets in relapsed pediatric AML and precision medicine therapies under current or planned clinical investigation.

Figure 2.

ADCs = antibody-drug conjugates, CAR = chimeric antigen receptor, FLT3R = FLT3 receptor, FOLR1 = folate receptor 1, HDACi = histone deacetylase inhibitors, HMAs = hypomethylating agents, KMT2A = lysine methyltransferase 2A, NK = natural killer. Figure was created using BioRender.com.